Hofmann S, Bezold R, Jaksch M, Obermaier-Kusser B, Mertens S, Kaufhold P, Rabl W, Hecker W, Gerbitz K D
Institute of Clinical Chemistry, Academic Hospital Schwabing, Munich, Germany.
Genomics. 1997 Jan 1;39(1):8-18. doi: 10.1006/geno.1996.4474.
Because Wolfram (or DIDMOAD) syndrome is supposed to be a mitochondrial (mt)-mediated disease, we investigated a group of eight DIDMOAD patients with respect to point mutations of the mtDNA thus far described as being associated with defined mitochondrial disorders such as MELAS, MERRF, and LHON. Furthermore, to screen DIDMOAD patients for other mtDNA defects we used Southern blot analysis to detect mtDNA length mutations and rearrangements as well as PCR-SSCP and direct sequencing to screen all ND genes (complex I of the respiratory chain), the 22 tRNAs, and a part of the cyt b gene for unknown mutations. As a disease control group, 17 LHON patients (harboring one of the primary LHON mutations) were included in this study because of the overlapping clinical symptoms (optic atrophy) in both syndromes. We compared mtDNA variants identified in DIDMOAD patients with those found in LHON patients as well as in a control group consisting of 67 healthy German blood donors. In total, the control group was characterized by 29 polymorphic sites in ND and tRNA genes that define certain major Caucasian haplotypes. We found that a cluster of nucleotide exchanges at nucleotide positions (nps) 4216 and 11,251 roughly discriminates controls (12/67 controls, 18%) from the disease groups (6/8 DIDMOAD patients, 75%; 10/17 LHON patients, 59%). All 4216-positive LHON patients (10 patients) were concentrated in a haplogroup defined by additional exchanges at nps 10,398, 12,612, and 13,708 (haplogroup A), while the bulk of 4216-positive DIDMOAD patients (5 patients) were found in a distinct haplogroup consisting of nucleotide exchanges at nps 4917, 10,463, 13,368, 14,233, and 15,928. The frequencies of both haplogroups were significantly lower in the control group versus the respective disease groups. A more detailed analysis was performed by sequencing the two hypervariable regions of the non-coding D-loop region from patients and controls and corroborated the ranging in the two major haplogroups. Thus, the different clinical features of the mitochondrial disease groups investigated here corresponded to different clusters of mtDNA variants, which might act as predisposing haplotypes, increasing the risk for disease.
由于沃夫勒姆(或 DIDMOAD)综合征被认为是一种由线粒体(mt)介导的疾病,我们对一组 8 名 DIDMOAD 患者进行了研究,检测了迄今为止已报道的与特定线粒体疾病(如 MELAS、MERRF 和 LHON)相关的 mtDNA 点突变。此外,为了筛查 DIDMOAD 患者是否存在其他 mtDNA 缺陷,我们采用 Southern 印迹分析来检测 mtDNA 长度突变和重排,同时利用 PCR - SSCP 和直接测序技术筛查所有 ND 基因(呼吸链复合体 I)、22 种 tRNA 以及细胞色素 b 基因的一部分,以寻找未知突变。作为疾病对照组,本研究纳入了 17 名 LHON 患者(携带一种主要的 LHON 突变),因为这两种综合征存在重叠的临床症状(视神经萎缩)。我们将 DIDMOAD 患者中鉴定出的 mtDNA 变异与 LHON 患者以及由 67 名健康德国献血者组成的对照组中发现的变异进行了比较。总体而言,对照组在 ND 和 tRNA 基因中有 29 个多态性位点,这些位点定义了某些主要的高加索单倍型。我们发现,核苷酸位置(nps)4216 和 11251 处的一组核苷酸交换大致可将对照组(67 名对照组中有 12 名,18%)与疾病组(8 名 DIDMOAD 患者中有 6 名,75%;17 名 LHON 患者中有 10 名,59%)区分开来。所有 4216 阳性的 LHON 患者(10 名患者)集中在一个由 nps 10398、12612 和 13708 处额外交换所定义的单倍群(单倍群 A)中,而大多数 4216 阳性的 DIDMOAD 患者(5 名患者)则位于一个由 nps 4917、10463、13368、14233 和 15928 处核苷酸交换组成的独特单倍群中。与各自的疾病组相比,这两个单倍群在对照组中的频率显著更低。通过对患者和对照组非编码 D - 环区域的两个高变区进行测序,进行了更详细的分析,证实了在这两个主要单倍群中的分布情况。因此,此处研究的线粒体疾病组的不同临床特征对应于不同的 mtDNA 变异簇,这些变异簇可能作为易感单倍型,增加患病风险。